Innodata, a U.S. provider of IT services and enterprise software, saw its stock surge more than 21% in premarket trading on Friday, August 9. The gains followed the announcement of record revenue growth of 66% in the second quarter, as well as upgraded guidance for the year.

Innodata stock surges on record revenue growth, Big Tech client news

Shares of Viemed Healthcare, a company that provides in-home respiratory support and has a market capitalization of $278.7 million, <a href="https://finance.yahoo.com/quote/VMD/">rose</a> nearly 10% on Thursday, August 8. The day before, the company reported upbeat earnings for the second quarter of 2024: net revenue had its best quarterly performance ever, having risen 27% year-over-year, while adjusted EBITDA was up 31%.

Home medical services provider Viemed climbs after record earnings

Citius Pharmaceuticals <a href="https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Receives-FDA-Approval-for-LYMPHIR-denileukin-diftitox-cxdl-Immunotherapy-for-the-Treatment-of-Adults-with-Relapsed-or-Refractory-Cutaneous-T-Cell-Lymphoma/default.aspx">announced</a> that the U.S. Food and Drug Administration (FDA) had approved its lymphoma drug LYMPHIR. This marks the first FDA approval for the drug developer. Despite this, quotes on Citius Pharmaceuticals shares plummeted 17% after the opening bell, followed by a slight rebound later. Earlier this week, Citius Pharma <a href="https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Announces-TenX-Keane-Shareholder-Approval-of-Merger-with-Citius-Oncology-Inc/default.aspx">announced</a> the spinoff of its oncology subsidiary and its merger with the SPAC TenX Keane Acquisition.

Citius Pharmaceuticals stock falls despite approval of its lymphoma drug

On Wednesday, August 7, Canada’s KITS Eyecare, a retailer of eyewear and contact lenses, <a href="https://ir.kits.com/news/news-details/2024/KITS-Eyecare-Reports-Record-Second-Quarter-2024-Results/default.aspx">reported</a> that its revenue grew 26% to a record CAD37.9 million (approximately $27.6 million) in the second quarter of 2024. Quotes on KITS shares closed 5% higher on the Toronto Stock Exchange. 

Eyewear and contact lens retailer KITS Eyecare reports record revenue

"A caravan of combine harvesters chew up the grassland under the open prairie sky. They hum along in staggered rows, on the way to fill up grain elevators in the distance. The air smells like a combination of a bakery, brewery, and grassland," <strong>Lionel Kambeitz</strong>, cofounder of Canada’s Above Food, poetically <a href="https://www.seechangemagazine.com/an-innovative-way-to-bring-sustainable-food-to-your-table/">describes</a> the business. Since its inception in 2019, the company has set an ambitious goal to revolutionize what it estimates as the $200 billion plant-based protein market. In its short history, the company has seen several mergers and acquisitions, gone public, and faced losses and working capital shortages. Nevertheless, Above Food claims it has the potential to double its current revenue.

Prairies and AI: How plant-based food manufacturer Above Food built its business

The explosive growth of the AI market has taken many tech stocks to record highs, but the Motley Fool <a href="https://www.fool.com/investing/2024/08/06/3-top-artificial-intelligence-ai-stocks-ready-for/">argues</a> that there are still hidden gems out there, highlighting three companies in particular: processor manufacturer AMD, cybersecurity company SentinelOne, and IT service provider Innodata. Each of them, though differing in size, has plenty of room to grow as the AI market expands, the Motley Fool contends.

The Motley Fool spotlights three AI stocks ready for ‘bull run’

Shares of the biotechnology company Equillium, with a market capitalization of $25.7 million, surged over 15% on Tuesday, August 6. The trigger <a href="https://www.equilliumbio.com/investors/press-releases/news-details/2024/Equillium-Announces-Positive-Interim-Analysis-from-Phase-3-EQUATOR-Study-of-Itolizumab-in-Acute-Graft-Versus-Host-Disease/default.aspx">was</a> positive interim results from the trial of its drug for graft-versus-host disease (GvHD), a condition in which a donor's immune cells attack a recipient's body, recognizing it as foreign. Now, Japan’s Ono Pharmaceutical can exercise a call option to purchase the rights to the drug for approximately $35 million.

Maker of transplant rejection drug Equillium sees shares rise after successful trial

Nonlethal weapons manufacturer Byrna Technologies may repurchase up to $10 million of its stock under a new buyback program. At the start of trading on Monday, August 5, quotes on Byrna were on the rise but eventually ended the session down 2%.

Nonlethal weapons manufacturer Byrna announces $10 million stock buyback

Citius Pharmaceuticals, a developer of drugs for bloodstream infections, lymphoma, and hemorrhoids, is one step closer to spinning off its oncology business as a separate Nasdaq-listed company. On Monday, August 5, shares of Citius Pharma rose nearly 3% on the news, despite a broader market <a href="https://kz.kursiv.media/2024-08-05/lktv-panic-selloff/">selloff</a>.

Lymphoma drug developer Citius Pharma finalizing spin-off of oncology division

On Friday, August 2, IES Holdings, which designs and installs integrated electrical and technology systems for a variety of end markets, released its results for the fiscal-2024 third quarter (ended June 30) and <a href="https://investors.ies-corporate.com/news-releases/news-release-details/ies-holdings-reports-fiscal-2024-third-quarter-results-board">announced</a> that the board of directors had approved a new $200 million stock buyback program. This announcement, along with upbeat revenue and operating income numbers, buoyed the stock, which added more than 7% later in the day.

Infrastructure company IES Holdings announces $200 million buyback, stock jumps

Quotes on shares of Inuvo, a provider of AI-driven advertising technology, rose almost 3.5% on Thursday, August 1, following the <a href="https://finance.yahoo.com/news/inuvo-secures-10-million-credit-120000907.html">announcement</a> of a new $10 million credit line.

Shares of AI-powered advertising technology provider Inuvo gain after loan announcement

Simply Wall St <a href="https://finance.yahoo.com/news/now-opportune-moment-examine-crexendo-192112329.html">sees</a> the stock of Crexendo, a provider of cloud platforms and services for businesses, as undervalued, believing it should be trading 50% higher.

Small caps